ijms-logo

Journal Browser

Journal Browser

Causalities and Regulations of Tumor Metastasis — in Memory of Professor Isaiah J. Fidler (1936–2020)

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 25315

Special Issue Editor


E-Mail Website
Guest Editor
Section of Cell Biology & Biophysics, Department of Biology, School of Science, National and Kapodistrian University of Athens (NKUA), Panepistimiopolis, Zografou, 15701 Athens, Greece
Interests: development; cancer; chemotherapy; metastasis; programmed cell death; metabolism; Drosophila aging; brain signaling; proteasome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The major cause of cancer-associated deaths is metastatic disease, rather than primary malignancy. Cancer cells can infrequently disseminate from primary tumors and subsequently seed new colonies in distant tissues, via a multistep process of genetic and/or epigenetic alterations, widely known as invasion–metastasis cascade. This sequential course mainly involves: (a) intravasation of escapers into the circulation, (b) tumor-cell protection against physical stress (hydrodynamic flow) and immune (neutrophil) attack, and (c) extravasation of the survivors through trans-endothelial migration. One central superprogram being contextually engaged in cancer metastasis is termed epithelial-to-mesenchymal transition (EMT). A series of master EMT-inducing transcription factors, such as Zeb1, Twist, Slug, and Snail, orchestrate and coordinate the loss of epithelial (usually, E-Cadherin-dependent) features, and the simultaneous acquisition of specific mesenchymal (usually, Vimentin-dependent) properties, thus endowing cancer cells with multiple malignant traits. Heterotypic signals, including TGF-βs and Wnts, released from the nearby, “reactive”, stroma that is composed of (myo)fibroblasts, endothelial, lymphoid, and myeloid cells, can activate the previously silent EMT route. Remarkably, it is the phenotypic plasticity of a “partial EMT” (“hybrid” in between EMT and MET (mesenchymal-to-epithelial transition)) state that seems to enhance tumor progression and metastasis. EMT commitment can also confer upon cancer cells important stem-cell attributes that usually serve as critical prerequisites for metastatic colonization. However, the biological underpinnings of adaptive mechanisms that control organ-specific tropism of metastatic cells remain poorly understood. Hitherto, no genetic mutation has been identified to be associated with progression to metastasis. Hence, despite the general principles of metastasis that have begun to emerge, detailed molecular circuitries, with oncogenic control nodes, are necessitated to be promptly elucidated, regarding the “causalities and regulations” of: (a) metastatic heterogeneity, (b) clonal origin of metastasis, (c) metastatic evolution, (d) organ microenvironment, (e) “intermediate EMT” programming, (f) radio- and/or chemotherapy resistance, (g) cancer-cell stemness, (h) metastatic dormancy, (i) metastatic signature, (j) metastatic stochasticity, and (k) metastatic determinism.

Special Statement: This Special Issue of “Causalities and Regulations of Tumor Metastasis” is dedicated to the memory of Professor Isaiah J. Fidler who passed away on 8 May 2020 (1936–2020). He was a pioneer in the field of tumor metastasis. Prof. Fidler published over 800 publications in peer-reviewed journals in a career of more than 50 years. He received countless awards that recognized his excellence and valued expertise in metastasis research.

Dr. Dimitrios J. Stravopodis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • chemoresistance
  • EMT
  • heterogeneity
  • MET
  • metastasis
  • signaling
  • stemness
  • stroma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (6 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 4003 KiB  
Article
High Mobility Group Box 1 Promotes Lung Cancer Cell Migration and Motility via Regulation of Dynamin-Related Protein 1
by Wei-Lun Liu, Chia-Yang Li, Wei-Chung Cheng, Chia-Yuan Chang, Yung-Hsiang Chen, Chi-Yu Lu, Shu-Chi Wang, Yu-Ru Liu, Meng-Hsuan Cheng, Inn-Wen Chong and Po-Len Liu
Int. J. Mol. Sci. 2021, 22(7), 3628; https://doi.org/10.3390/ijms22073628 - 31 Mar 2021
Cited by 10 | Viewed by 3056
Abstract
High mobility group box 1 (HMGB1) has been demonstrated to promote the migration and invasion of non-small cell lung cancer (NSCLC). However, the mechanism of action of HMGB1 in regulating tumor mobility remains unclear. Therefore, we aimed to investigate whether HMGB1 affects mitochondria [...] Read more.
High mobility group box 1 (HMGB1) has been demonstrated to promote the migration and invasion of non-small cell lung cancer (NSCLC). However, the mechanism of action of HMGB1 in regulating tumor mobility remains unclear. Therefore, we aimed to investigate whether HMGB1 affects mitochondria distribution and regulates dynamin-related protein 1 (DRP1)-mediated lamellipodia/filopodia formation to promote NSCLC migration. The regulation of mitochondrial membrane tension, dynamics, polarization, fission process, and cytoskeletal rearrangements in lung cancer cells by HMGB1 was analyzed using confocal microscopy. The HMGB1-mediated regulation of DRP1 phosphorylation and colocalization was determined using immunostaining and co-immunoprecipitation assays. The tumorigenic potential of HMGB1 was assessed in vivo and further confirmed using NSCLC patient samples. Our results showed that HMGB1 increased the polarity and mobility of cells (mainly by regulating the cytoskeletal system actin and microtubule dynamics and distribution), promoted the formation of lamellipodia/filopodia, and enhanced the expression and phosphorylation of DRP1 in both the nucleus and cytoplasm. In addition, HMGB1 and DRP1 expressions were positively correlated and exhibited poor prognosis and survival in patients with lung cancer. Collectively, HMGB1 plays a key role in the formation of lamellipodia and filopodia by regulating cytoskeleton dynamics and DRP1 expression to promote lung cancer migration. Full article
Show Figures

Figure 1

Review

Jump to: Research

13 pages, 552 KiB  
Review
Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
by Ioannis A. Vathiotis, Georgia Gomatou, Dimitrios J. Stravopodis and Nikolaos Syrigos
Int. J. Mol. Sci. 2021, 22(10), 5383; https://doi.org/10.3390/ijms22105383 - 20 May 2021
Cited by 12 | Viewed by 3028
Abstract
Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has long been implicated in modeling antitumor immunity; PD-1/PD-L1 axis inhibitors exert their antitumor effects by relieving PD-L1-mediated suppression on tumor-infiltrating T lymphocytes. However, recent studies have unveiled a distinct, tumor-intrinsic, potential [...] Read more.
Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has long been implicated in modeling antitumor immunity; PD-1/PD-L1 axis inhibitors exert their antitumor effects by relieving PD-L1-mediated suppression on tumor-infiltrating T lymphocytes. However, recent studies have unveiled a distinct, tumor-intrinsic, potential role for PD-L1. In this review, we focus on tumor-intrinsic PD-L1 signaling and delve into preclinical evidence linking PD-L1 protein expression with features of epithelial-to-mesenchymal transition program, cancer stemness and known oncogenic pathways. We further summarize data from studies supporting the prognostic significance of PD-L1 in different tumor types. We show that PD-L1 may indeed have oncogenic potential and act as a regulator of tumor progression and metastasis. Full article
Show Figures

Figure 1

16 pages, 7000 KiB  
Review
Tumor Dormancy: Implications for Invasion and Metastasis
by Georgia Gomatou, Nikolaos Syrigos, Ioannis A. Vathiotis and Elias A. Kotteas
Int. J. Mol. Sci. 2021, 22(9), 4862; https://doi.org/10.3390/ijms22094862 - 4 May 2021
Cited by 32 | Viewed by 5061
Abstract
Tumor dormancy refers to a critical stage of cancer development when tumor cells are present, but cancer does not progress. It includes both the concept of cellular dormancy, indicating the reversible switch of a cancer cell to a quiescent state, and that of [...] Read more.
Tumor dormancy refers to a critical stage of cancer development when tumor cells are present, but cancer does not progress. It includes both the concept of cellular dormancy, indicating the reversible switch of a cancer cell to a quiescent state, and that of tumor mass dormancy, indicating the presence of neoplastic masses that have reached cell population equilibrium via balanced growth/apoptosis rates. Tumor dormancy provides the conceptual framework, potentially explaining a major challenge in clinical oncology, tumor recurrence, which may occur years after cancer diagnosis. The mechanisms by which tumors are kept dormant, and what triggers their reawakening, are fundamental questions in cancer biology. It seems that a plethora of intracellular pathways and extracellular factors are involved in this process, rewiring the cells to plastically alter their metabolic and proliferative status. This phenomenon is highly dynamic in space and time. Mechanistic insights into both cellular and tumor dormancy have provided the rationale for targeting this otherwise stable period of cancer development, in order to prevent recurrence and maximize therapeutic benefit. Full article
Show Figures

Figure 1

18 pages, 548 KiB  
Review
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma
by Nikolaos Giannakoulas, Ioannis Ntanasis-Stathopoulos and Evangelos Terpos
Int. J. Mol. Sci. 2021, 22(9), 4462; https://doi.org/10.3390/ijms22094462 - 24 Apr 2021
Cited by 52 | Viewed by 5213
Abstract
The development and effectiveness of novel therapies in multiple myeloma have been established in large clinical trials. However, multiple myeloma remains an incurable malignancy despite significant therapeutic advances. Accumulating data have elucidated our understanding of the genetic background of the malignant plasma cells [...] Read more.
The development and effectiveness of novel therapies in multiple myeloma have been established in large clinical trials. However, multiple myeloma remains an incurable malignancy despite significant therapeutic advances. Accumulating data have elucidated our understanding of the genetic background of the malignant plasma cells along with the role of the bone marrow microenvironment. Currently, the interaction among myeloma cells and the components of the microenvironment are considered crucial in multiple myeloma pathogenesis. Adhesion molecules, cytokines and the extracellular matrix play a critical role in the interplay among genetically transformed clonal plasma cells and stromal cells, leading to the proliferation, progression and survival of myeloma cells. In this review, we provide an overview of the multifaceted role of the bone marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Full article
Show Figures

Figure 1

23 pages, 1663 KiB  
Review
Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis
by Mariam Markouli, Dimitrios Strepkos, Efthimia K. Basdra, Athanasios G. Papavassiliou and Christina Piperi
Int. J. Mol. Sci. 2021, 22(5), 2778; https://doi.org/10.3390/ijms22052778 - 9 Mar 2021
Cited by 21 | Viewed by 4847
Abstract
Tumor aggressiveness and progression is highly dependent on the process of metastasis, regulated by the coordinated interplay of genetic and epigenetic mechanisms. Metastasis involves several steps of epithelial to mesenchymal transition (EMT), anoikis resistance, intra- and extravasation, and new tissue colonization. EMT is [...] Read more.
Tumor aggressiveness and progression is highly dependent on the process of metastasis, regulated by the coordinated interplay of genetic and epigenetic mechanisms. Metastasis involves several steps of epithelial to mesenchymal transition (EMT), anoikis resistance, intra- and extravasation, and new tissue colonization. EMT is considered as the most critical process allowing cancer cells to switch their epithelial characteristics and acquire mesenchymal properties. Emerging evidence demonstrates that epigenetics mechanisms, DNA methylation, histone modifications, and non-coding RNAs participate in the widespread changes of gene expression that characterize the metastatic phenotype. At the chromatin level, active and repressive histone post-translational modifications (PTM) in association with pleiotropic transcription factors regulate pivotal genes involved in the initiation of the EMT process as well as in intravasation and anoikis resistance, playing a central role in the progression of tumors. Herein, we discuss the main epigenetic mechanisms associated with the different steps of metastatic process, focusing in particular on the prominent role of histone modifications and the modifying enzymes that mediate transcriptional regulation of genes associated with tumor progression. We further discuss the development of novel treatment strategies targeting the reversibility of histone modifications and highlight their importance in the future of cancer therapy. Full article
Show Figures

Figure 1

18 pages, 333 KiB  
Review
Clinical Perspectives of ERCC1 in Bladder Cancer
by Konstantinos Koutsoukos, Angeliki Andrikopoulou, Nikos Dedes, Flora Zagouri, Aristotelis Bamias and Meletios-Athanasios Dimopoulos
Int. J. Mol. Sci. 2020, 21(22), 8829; https://doi.org/10.3390/ijms21228829 - 22 Nov 2020
Cited by 10 | Viewed by 3147
Abstract
ERCC1 is a key regulator of nucleotide excision repair (NER) pathway that repairs bulky DNA adducts, including intrastrand DNA adducts and interstrand crosslinks (ICLs). Overexpression of ERCC1 has been linked to increased DNA repair capacity and platinum resistance in solid tumors. Multiple single [...] Read more.
ERCC1 is a key regulator of nucleotide excision repair (NER) pathway that repairs bulky DNA adducts, including intrastrand DNA adducts and interstrand crosslinks (ICLs). Overexpression of ERCC1 has been linked to increased DNA repair capacity and platinum resistance in solid tumors. Multiple single nucleotide polymorphisms (SNPs) have been detected in ERCC1 gene that may affect ERCC1 protein expression. Platinum-based treatment remains the cornerstone of urothelial cancer treatment. Given the expanding application of neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer, there is an emerging need for biomarkers that could distinguish potential responders to cisplatin treatment. Extensive research has been done regarding the prognostic and predictive role of ERCC1 gene expression and polymorphisms in bladder cancer. Moreover, novel compounds have been recently developed to target ERCC1 protein function in order to maximize sensitivity to cisplatin. We aim to review all the existing literature regarding the role of the ERCC1 gene in bladder cancer and address future perspectives for its clinical application. Full article
Back to TopTop